ArticleBiomedicines2022
First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation.
Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- HDL proteome: from its characterization to quantitative measurements in particle subspecies and functional associations.Expert review of proteomics · 2025Review
- High-density lipoproteins and COVID-19: preparing the next pandemic.Journal of lipid research · 2025Review
- HDL-replacement therapy: From traditional to emerging clinical applications.Atherosclerosis plus · 2025Review
- HDL proteome and apolipoproteins concentrations in severe ICU COVID-19 patients.Lipids in health and disease · 2025Article
- Metabolomic Characterisation of Low-Density Lipoproteins Isolated from Iodixanol and KBr-Based Density Gradient Ultracentrifugation.Metabolites · 2025Article
- Gut Microbiota Metabolites Targeting the Immune Response in Sepsis: Mechanisms and Therapies.International journal of general medicine · 2025Review
- The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies.Metabolites · 2024Review
- HDL as a Treatment Target: Should We Abandon This Idea?Current atherosclerosis reports · 2023Review
- HDL-Related Parameters and COVID-19 Mortality: The Importance of HDL Function.Antioxidants (Basel, Switzerland) · 2023Article
- Beneficial effects of recombinant CER-001 high-density lipoprotein infusion in sepsis: results from a bench to bedside translational research project.BMC medicine · 2023Article
- Mannose-Coated Reconstituted Lipoprotein Nanoparticles for the Targeting of Tumor-Associated Macrophages: Optimization, Characterization, and In Vitro Evaluation of Effectiveness.Pharmaceutics · 2023Article
- A Current Update on the Role of HDL-Based Nanomedicine in Targeting Macrophages in Cardiovascular Disease.Pharmaceutics · 2023Review
- High-density lipoprotein revisited: biological functions and clinical relevance.European heart journal · 2023Review
- Impact of High-Density Lipoproteins on Sepsis.International journal of molecular sciences · 2022Review
- Low HDL Cholesterol Efflux Capacity Indicates a Fatal Course of COVID-19.Antioxidants (Basel, Switzerland) · 2022Article
- Changes in HDL cholesterol, particles, and function associate with pediatric COVID-19 severity.Frontiers in cardiovascular medicine · 2022Article
- Crosstalk between high-density lipoproteins and endothelial cells in health and disease: Insights into sex-dependent modulation.Frontiers in cardiovascular medicine · 2022Review
- Apolipoprotein-A-I for severe COVID-19-induced hyperinflammatory states: A prospective case study.Frontiers in pharmacology · 2022Article
- Development of activated endothelial targeted high-density lipoprotein nanoparticles.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
Abstract
High-density lipoproteins (HDLs) have multiple endothelioprotective properties. During SARS-CoV-2 infection, HDL-cholesterol (HDL-C) concentration is markedly reduced, and studies have described severe impairment of the functionality of HDL particles. Here, we report a multi-omic investigation of the first administration of recombinant HDL (rHDL) particles in a severe COVID-19 patient in an intensive care unit. Plasma ApoA1 increased and HDL-C decreased after each recombinant HDL injection, suggesting that these particles were functional in terms of reverse cholesterol transport. The proportion of large HDL particles also increased after injection of recombinant HDL. Shotgun proteomics performed on HDLs isolated by ultracentrifugation indicated that ApoA1 was more abundant after injections whereas most of the pro-inflammatory proteins identified were less abundant. Assessment of Serum amyloid A-1, inflammatory markers, and cytokines showed a significant decrease for most of them during recombinant HDL infusion. Our results suggest that recombinant HDL infusion is feasible and a potential therapeutic strategy to be explored in COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.